BALTIMORE--(BUSINESS WIRE)--Cerecor Inc., a clinical-stage biopharmaceutical company with the goal of becoming a leader in the development of innovative drugs that make a difference in the lives of patients with neurological and psychiatric disorders, today announced that it has appointed Ronald Marcus, MD, as Chief Medical Officer and Head of Regulatory Affairs. Dr. Marcus has more than 20 years of experience in the development of neuroscience drugs at both Spinifex and Bristol-Myers Squibb (BMS). In addition, the Company has appointed Uli Hacksell, PhD, as Chairman of the Board of Directors. Dr. Hacksell was most recently CEO of ACADIA Pharmaceuticals Inc. (ACADIA).
Help employers find you! Check out all the jobs and post your resume.
